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Background: The occurrence of synchronous or metachronous renal cell carcinoma and pancreatic tumors has
been described only in a few cases in the scientific literature. The study of double primary cancers is important
because it might provide understanding of a shared genetic basis of different solid tumors and to detect patients
at risk for secondary malignancy.
Methods: In a combined analysis of patient registries from University Departments of Urology and Visceral Surgery,
1178 patients with pancreatic tumors and 518 patients with renal cell carcinoma treated between 2001 and 2008
were evaluated,
Results: Overall 16 patients with renal cancer and synchronous (n = 6) or metachronous (n = 10) primary pancreatic
tumors were detected. The median survival of all patients was 12.6 months, for the patients with synchronous
resections 25.7 months and for the patients with metachronous resections 12.2 months, respectively.
Conclusions: The association between these two etiologies of malignancy demands more detailed epidemiological
and molecular investigation. Clinical outcomes would support a resection as a recommended clinically valid option.
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cancersBackground
Recent improvements in the prognosis of cancer patients
have led to an increase in the incidence of second pri-
mary cancers, and the frequency of multiple primary
malignant tumors is expected to increase as the popula-
tion ages [1]. Moreover, the widespread application of
computertomography (CT) and ultrasound (US) for
other indications has led to increased detection of renal
and pancreatic tumors as an incidental finding [2]. These
tumors are typically smaller than those that produce
symptoms and are more likely to be resectable. The fre-
quency of multiple primary tumors among all cases of
malignancy has been reported as 1 to 3% [3]. The fre-
quency of pancreatic cancer in association with cancer
of other organs is estimated to range from 1% to as high* Correspondence: bruno.schmied@kssg.ch
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reproduction in any medium, provided the oras 20% [4], with malignancies predominately of the
stomach, colon, thyroid, and genitourinary tract [5]. Sec-
ond malignancies reported to be associated with renal
cell carcinoma (RCC) include Non-Hodgkin’s lymph-
oma, multiple myeloma, chronic lymphatic leukaemia,
melanoma and cancers of the bladder, prostate, breast,
rectum, and lung with an incidence that varies from 5 to
27% [6,7]. There has only been infrequent reporting of
synchronous or metachronous tumors of the pancreas
and the kidney [5,7,8].
RCC, originating in the renal cortex and accounting
for 80% to 85% of malignant kidney tumors, represents
2% to 3% of all cancers [9], with the highest incidence
occurring in more developed countries. Rates of RCC
vary internationally more than 10-fold, suggesting a
strong role for exogenous risk factors, in addition to
possible roles of geographic differences in genetic sus-
ceptibility and diagnostic variability. Several risk factors
have been identified including increased age, male sex,
smoking, obesity, long-term dialysis, and several geneticLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Hippel-Lindau disease (VHL) and tuberose sclerosis
[10,11]. Pancreatic manifestations of the rare autosomal
dominant VHL disease include simple cysts, diffuse cys-
tic changes, cystadenomas and tumors [12]. Approxi-
mately 35% to 45% of patients with VHL develop kidney
cancers that are of clear cell histology, often bilateral
and/or multifocal and is a major cause of death among
these patients [12]. Cigarette smoking is the most con-
sistently established causal risk factor for RCC and dou-
bles the likelihood of RCC and contributes to as many
as one third of all cases [13]. Second primary malignan-
cies associated with RCC include those of urinary blad-
der, prostate, rectal, and lung cancer, as well as non-
Hodgkin’s lymphoma and melanoma [7].
Pancreatic ductal adenocarcinoma (PDAC) comprises
2% of all cancer diagnoses and is a highly malignant car-
cinoma, making it the forth leading cause of cancer-
related death [14]. Unfortunately, due to the late presen-
tation of symptoms, only 10% to 20% of patients are
candidates for surgical resection, which remains the only
viable chance for cure [15]. The precise causes of pan-
creatic cancer have not yet been determined, but re-
search indicates that certain risk factors may be
associated with an increased probability of developing
pancreatic cancer. These factors include smoking, age,
race, family history, obesity, chronic pancreatitis, envir-
onmental factors, and genetic predisposition [16,17].
Ten per cent of all PDAC cases are related to genetic
disorders, e.g. BRCA1 and BRCA2 gene mutations, her-
editary non-polyposis colorectal cancer (HNPCC, Lynch
syndrome) and familial atypical mole-malignant melan-
oma (FAMMM) [18-20].
To the best of our knowledge, only few cases with syn-
chronous or metachronous occurrence of both tumors
have been reported in the literature. In the present study
data from two registries (Department of Surgery and De-
partment of Urology) were screened. We examined for
the first time surgical outcome, and prognosis of coexist-
ing primary renal and pancreatic tumors in the same pa-
tient observed and treated either synchronously or
metachronously.
Methods
This study prospectively analyzed 1178 patients who
underwent exploration or resection for PDAC or pancre-
atic cystic tumors at the Department of Surgery, from
October 2001 through March 2008 and 518 patients
with RCC treated during the same time period at the
Departement of Urology. Among these patients, we ana-
lyzed those who had undergone a surgical procedure for
pancreatic tumors and simultaneous or preceding sur-
gery for synchronous or metachronous renal tumors.
Synchronous second primary tumors were defined astumors diagnosed at the same time or within 12 months
before the diagnosis of the first primary tumor. If both
tumors were present at the same time, the oncological
resection was performed interdisciplinary through a
standard median laparotomy. Metachronous pancreatic
tumors occurred more than 12 months after the primary
renal tumor. Patients with ampullary adenocarcinomas,
distal bile-duct carcinomas, and other malignancies were
excluded from the study. PDAC and neoplastic cystic
pancreatic tumors were both defined as pancreatic
tumors in the current study. This study identified a total
of 16 patients with double primary tumors. Sixteen par-
tial or total nephrectomies and exploration or resection
for pancreatic tumors were perfomed within 0 to
205 months of diagnosis. The synchronous second pri-
mary tumors were confirmed by pathological diagnosis
after resection. The demographic and clinical variables,
including age, sex, operative procedure, morbidity, mor-
tality and hospital course were collected. All patients
were regularly followed in the outpatient clinic, or the
patients’s primary physician was personally contacted or
until patients’ death.
Morbidity and mortality
Major postoperative complications were defined as
delayed gastric emptying (DGE), pancreatic fistula,
intraabdominal abscess, hemorrhage, reoperation and
pneumonia. Pancreatic fistula, DGE and intraabdominal
hemorrhage were defined according to the International
Study Group of Pancreatic Surgery (ISGPS) [21-23].
Postoperative mortality was defined as death within
30 days of surgery.
Statistical analysis
Overall survival was measured from the date of nephrec-
tomy to the date of last follow-up or death. SAS software
(Release 9.1, SAS Institute, Inc., Cary, NC, USA) was
used for statistical analysis. Quantitative variables are
expressed as median and range. Overall survival from
the date of pancreas operation was calculated by the
Kaplan-Meier estimate. Two-sided P-values were always
computed and a difference was considered statistically
significant at P ≤ 0.05.
Results
Clinicopathological features
Among the 1178 patients with PDAC or cystic tumor of
the pancreas, 16 (1.35%) were also diagnosed with either
synchronous or metachronous renal tumor. The patients
ranged on age from 52 to 77 years (median 69 years),
and showed a male predominance with 12 men and 4
women. There were 10 metachronous and 6 synchron-
ous double tumor patients. Among these 6 synchronous
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median laparotomy. By the time pancreatic tumor was
diagnosed, patients had received preceding nephrecto-
mies for renal tumors 1.25 - 205 months before (median:
78.0 months). Histologically all renal tumors were RCC
variants and 12 of the 16 pancreatic tumors were PDAC
and the remaining 4 were intraductal papillary mucinous
neoplasms (IPMN) (Table 1). Demographic, clinical and
operative data, including age, sex, and the different types
of renal and pancreatic resection for the entire cohort of
16 patients are given in Table 1.
Treatment and prognosis
All 16 patients underwent either explorative laparotomy
or pancreatic resection for pancreatic tumors. The treat-
ment modalities for the pancreatic tumor patients
included: distal pancreatectomy in 1 patient, total pan-
createctomy in 3, pylorus-preserving pancreatoduode-
nectomy in 7, palliative bypass operation in 4 patients,
and operation finished as an explorative laparotomy due
to locally advanced tumor or distant mestastases in 1
patient.
Surgical complications occurred in 4 patients (25%). The
most common postoperative complication was DGE
(n=2). Other complications included 1 intra-abdominal
hemorrhage Grade B and 1 pancreatic fistulas (1 Grade A).
Re-operation was necessary in 2 patients (12.5%) after me-
dian 11 (range 1–30) days. The median hospital stay for all
patients was 25.6 (range 7 – 167) days.
The median follow-up duration was 12.6 months with
a range of 1.5-35 months. During the follow-up periodable 1 Patient characteristics and surgical procedures




70 M PDAC ppWhipple Clear cell RCC
72 W PDAC ppWhipple Clear cell RCC
70 M PDAC ppWhipple Clear cell RCC
68 M PDAC Double bypass RCC
77 W PDAC Total pancreatectomy RCC
68 M PDAC Double bypass RCC
77 M PDAC Exploration RCC
71 M PDAC ppWhippe RCC
71 M PDAC ppWhipple Pap. RCC
0 68 M PDAC Double bypass RCC
1 55 W PDAC Left resection RCC
2 52 M IPMN ppWhipple Cystic RCC
3 65 W IPMN ppWhipple RCC
4 71 M IPMN Total pancreatectomy Pap. RCC
5 73 M IPMN Total pancreatectomy RCC
6 75 M PDAC Gastroenterostomy Pap. RCC11 patients died because of either pancreatic cancer or
its recurrence, whereas no patient died due to recurrent
RCC. Five patients are alive at present time. Figure 1
shows the comparison of the median survival rates be-
tween the patients treated for RCC alone (n = 518), the
corresponding pancreatic tumor cohort (n = 1178) with
either PDAC or IPMN and the 16 patients with double
primary tumors (p < 0.0001). Although lacking statistical
significance, synchronous resection had a longer median
survival of 25.7 months compared to metachronous re-
section (12.2 months) (p = 0.49; Figure 2).
Discussion
Due to the aid of radiologic diagnostic tools, mass
screening, increasing patient age [2] and improving sur-
vival rates for patients with neoplastic disease, there has
been an increase in the rate of detected synchronous
and metachronous second primary cancers. Although
the mechanisms involved in the development of multiple
primary cancers are not fully understood, several factors
have been implicated. These findings are complex, and
include environmental factors (tobacco and alcohol
abuse, occupation, pollution), genetic predisposition,
previous medical treatment (radio- or chemotherapy),
gender-specific factors, hormonal factors, and inter-
action of these factors [24]. Studies examining genetic
factors found that microsatellite instability was more fre-
quent observed in multiple primary cancers than in
sporadic cancers [25]. The incidence of double primary
cancer has been carried out by the review of cancer





Partial neph. 0 Synchronous 35 Alive
nephrectomy 94 Metachronous 14 Dead
Partial neph. 0 Synchronous 5.25 Dead
Nephrectomy 119 Metachronous 4 Dead
Nephrectomy 152 Metachronous 12.25 Dead
Partial neph. 205 Metachronous 13 Dead
Nephrectomy 94 Metachronous 2.25 Dead
Partial neph. 84 Metachronous 12.5 Dead
nephrectomy 0 Synchronous 3.25 Dead
Partial neph. 135 Metachronous 0 Dead
Nephrectomy 135 Metachronous 17 Alive
Partial neph. 0 Synchronous 8 Alive
Nephrectomy 3 Synchronous 27.75 Dead
Partial neph. 1.25 Synchronous 14 Alive
Partial neph. 205 Metachronous 32 Alive
nephrectomy 21 Metachronous 1.5 Dead
Figure 1 Overall survival of RCC and pancreatic tumors.
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ing pancreatic and renal cell carcinoma was reported by
Sasaki et al. in 1969 [26]. Since then, only a few more
case reports have been published of this coincidence
with the largest group including 6 patients. Alexakis
et al. presented 2 patients with RCC and synchronous
primary PDAC [8].
Several factors may account for variations in the inci-
dence of pancreatic cancer between different countries.
Since advanced age is an important factor related to
pancreatic cancer, it can be anticipated that the large



























Figure 2 Overall survival of synchronous versus metachronous pancrlargely accounts for the high incidence of PDAC in these
countries [16]. The overall reported incidence of PDAC
associated with other organ malignancies is 1% to 20%
[4]. Kamisawa et al. found that pancreatic cancer was
associated with a high incidence of malignancies of the
gastrointestinal tract, especially the stomach [27]. Gerdes
et al. investigated 69 patients with PDAC and found 13
patients (19%) suffering from second primary malignan-
cies [5], but none had RCC. A study of pancreatic cancer
found 134 (5.6%) associated malignancies in 2394 autop-
sies including 7 with RCC (0.29%) [4]. Rabbani et al.




ous (n=6; 25.7 months median survival)
nous (n=10; 12.2 months median survival)
eatic tumor resection.
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tate, bladder and colorectal cancer and Non-Hodgkin’s
lymphoma but no PDAC [10].
Several hereditary cancer syndromes coincide with an
increased risk of pancreatic cancer. PDAC is seen in
some breast cancer families with BRCA1 and BRCA2
mutations [18]. Affected family members of the
FAMMM as well as those with a positive family history
of ataxia-telangiectasia have much higher risk of devel-
oping PDAC compared with the general population [19].
Patients with HNPCC have an increased risk of pancre-
atic cancer as well as stomach, breast, small bowel,
endometrial, and renal pelvis cancer [20]. None of the
histories of the patients in the current study indicated
any one of these rare syndromes.
Patients with a RCC have a significantly higher risk of
other subsequent primary malignancies [6,24]. While
prevalence studies based on autopsy series have identi-
fied a 30% to 40% incidence of other primary malignan-
cies in RCC patients, cohort studies have identified rates
of 4.5 to 27.4% [6,7]. A study by Czene et al. clearly indi-
cates that patients with RCC are at increased risk of
other cancers not only the first year after primary diag-
nosis, but also after more than 10 years [28]. Regarding
second primary pancreatic cancers in RCC patients, en-
vironmental factors, such as dietry habits or tobacco use,
and genetic factors have also been suggested to be risk
factors [29]. Although this study did not examine the
risk factors for both primary cancers patients, tobacco
cigarette smoking is a common environmental risk fac-
tor of both cancers, approximating to a 2-fold relative
risk [30]. VHL disease is a familial multiple-cancer syn-
drome characterized by numerous cystic and solid neo-
plasms [12]. More than one tumor in the brain or eye,
or a single tumor in the brain or eye plus one elsewhere
in the body, such as in the pancreas, kidney, liver, or ad-
renal gland are chraracteristic to diagnose VHL. Pancre-
atic cysts, serous cystadenomas and the more serious
pancreatic neuroendocrine tumors but not PDAC arise
in patients with VHL [12]. Nevertheless, we believe that
there could be a new association between these two pri-
mary tumors. Further analytic epidemiological studies,
including evaluation of gene-environment interactions,
are needed to specifically identify reasons for double
pancreatic-kidney tumors.
This reported “novel coincidence” of synchronous or
metachronous renal cell carcinoma and pancreatic tumors
in our study may be due to changes in modern medicine
over time. Radiological diagnostic tools were considerably
developed and diagnostic accuracy improved over the
intervening period. It may be also attributable to biases of
the specialization of each institution, referral patterns, and
local environmental factors. The specialized nature of a
cancer center like our institution allows more accuratediagnosis of primary and secondary cancers, in addition to
more detailed information on staging and follow-up.
Considering the trend that the peak age of cancer
patients and the incidence of cancer are increasing, the
present study cautions that physicians, urologists and
surgeons should consider the appearance of synchronous
or metachronous pancreatic tumors in RCC patients. Be-
cause patients diagnosed with pancreatic cancer have a
relatively short survival time, second primary cancer is
rarely detected in these patients. Therefore, the progno-
sis of patients with double cancers including pancreatic
cancer mainly depends on the prognosis of the pancre-
atic malignancy.
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